A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate

被引：2
作者：
Pashaj, Etleva [1 ]
Cortesi, Laura [1 ]
Proietto, Manuela [1 ]
Bonacorsi, Goretta [1 ]
Liardo, Eliana [1 ]
Federico, Massimo [1 ]
机构：
[1] Univ Modena & Reggio Emilia, Dept Oncol Haematol & Resp Dis, I-41100 Modena, Italy
来源：
FUTURE ONCOLOGY | 2013年 / 9卷 / 10期
关键词：
bone marrow metastasis; breast cancer; eribulin; LONG-TERM EFFICACY; ZOLEDRONIC ACID; DOUBLE-BLIND; PHASE-II; MECHANISMS; DISEASE; SAFETY;
D O I：
10.2217/fon.13.158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: We report our experience with eribulin mesylate in a pancytopenic heavily pretreated patient with multiple bone metastases and bone marrow infiltration from breast cancer. Methods: Eribulin mesylate was given at 1.4 mg/m(2) on day 1 and 8 every 3 weeks for a total of 11 courses. Results: After seven cycles, evaluation with a bone marrow biopsy showed a large decrease of neoplastic involvement with substitution of osteolitic lesions for the osteoaddensant type. No unexpected acute toxicity was observed. Conclusion: To our knowledge, this represents the first report of bone marrow metastases from breast cancer treated with eribulin mesylate that obtained an improvement of hematopoietic values with an acceptable profile of tolerability and good compliance for the subject.
引用
收藏
页码：1437 / 1442
页数：6
相关论文
共 15 条
[1]   A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer [J].
Aogi, K. ;
Iwata, H. ;
Masuda, N. ;
Mukai, H. ;
Yoshida, M. ;
Rai, Y. ;
Taguchi, K. ;
Sasaki, Y. ;
Takashima, S. .
ANNALS OF ONCOLOGY, 2012, 23 (06) :1441-1448
[2]   International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy [J].
Cardoso, Fatima ;
Bedard, Philippe L. ;
Winer, Eric P. ;
Pagani, Olivia ;
Senkus-Konefka, Elzbieta ;
Fallowfield, Lesley J. ;
Kyriakides, Stella ;
Costa, Alberto ;
Cufer, Tanja ;
Albain, Kathy S. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (17) :1174-1181
[3]   Metastatic bone disease: clinical features, pathophysiology and treatment strategies [J].
Coleman, RE .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :165-176
[4]   Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].
Cortes, Javier ;
O'Shaughnessy, Joyce ;
Loesch, David ;
Blum, Joanne L. ;
Vahdat, Linda T. ;
Petrakova, Katarina ;
Chollet, Philippe ;
Manikas, Alexey ;
Dieras, Veronique ;
Delozier, Thierry ;
Vladimirov, Vladimir ;
Cardoso, Fatima ;
Koh, Han ;
Bougnoux, Philippe ;
Dutcus, Corina E. ;
Seegobin, Seth ;
Mir, Denis ;
Meneses, Nicole ;
Wanders, Jantien ;
Twelves, Chris .
LANCET, 2011, 377 (9769) :914-923
[5]  
Freyer, 2000, Eur J Intern Med, V11, P329, DOI 10.1016/S0953-6205(00)00121-7
[6]   Bone imaging in metastatic breast cancer [J].
Hamaoka, T ;
Madewell, JE ;
Podoloff, DA ;
Hortobagyi, GN ;
Ueno, NT .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2942-2953
[7]   ESTROGEN AND PROGESTERONE-RECEPTOR CONCORDANCE BETWEEN PRIMARY AND RECURRENT BREAST-CANCER [J].
LI, BDL ;
BYSKOSH, A ;
MOLTENI, A ;
DUDA, RB .
JOURNAL OF SURGICAL ONCOLOGY, 1994, 57 (02) :71-77
[8]   Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone Metastases [J].
Lipton, Allan ;
Steger, Guenther G. ;
Figueroa, Jazmin ;
Alvarado, Cristina ;
Solal-Celigny, Philippe ;
Body, Jean-Jacques ;
de Boer, Richard ;
Berardi, Rossana ;
Gascon, Pere ;
Tonkin, Katia S. ;
Coleman, Robert ;
Paterson, Alexander H. G. ;
Peterson, Mark C. ;
Fan, Michelle ;
Kinsey, Amy ;
Jun, Susie .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) :4431-4437
[9]  
Pertschuk Louis P., 1999, Breast J, V5, P369, DOI 10.1046/j.1524-4741.1999.97088.x
[10]   Mechanisms of disease: Mechanisms of bone metastasis [J].
Roodman, GD .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1655-1664
12